Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00535522 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00535522: Completed Phase 1 study, sponsored by Millennium Pharmaceuticals.
NCT00535522 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00535522, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
Interventions
- DRUG TAK-285 Dose Escalation Cohorts
- DRUG TAK-285 Recommended Phase 2 Dosing Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT00535522 record still lists
NCT00535522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which TAK-285 Dose Escalation Cohorts is the first listed.
NCT00535522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00535522 about?
NCT00535522 is a clinical study titled "A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer". The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
What is the current status of trial NCT00535522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00535522?
The interventions under investigation include: TAK-285 Dose Escalation Cohorts (DRUG), TAK-285 Recommended Phase 2 Dosing Cohort (DRUG).
Who is sponsoring clinical trial NCT00535522?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00535522's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia